Talk to an expert

Targeted DRUG-seq kits

Massively multiplexed and targeted RNA-seq directly on cell, organoid and tissue lysates - no need for prior RNA extraction.

Compatible with Illumina®, AVITI™ and MGI sequencing systems.

Get a quote


The MERCURIUS™ Targeted DRUG-seq kits  offer the most comprehensive, high-throughput, and cost-efficient solution for targeted gene expression analysis projects. The kits contain all the oligos and enzymes needed to go from 2D cell cultures to sequencing-ready libraries.

Custom-developed targeted panels

Users communicate their targets of interest, and we will develop ad-hoc detection panels.


Up to 100 targets

Experimentally validated panels for differential expression analysis.


No RNA extraction needed

An optimized lysis buffer for RNA solubilization.


One-day lab workflow

Convenient and short protocol from samples to sequencing-ready libraries in one day.

What we do


Targeted DRUG-seq kits

The production of our Targeted DRUG-seq kits starts with the client providing us with their genes of interest. We then develop a corresponding custom detection panel and validate it directly using their RNA samples.

During the development process, we provide our clients with our proprietary Cell Lysis Buffer. This buffer is optimized for both cell lysis and downstream enzymatic reactions, eliminating the need for RNA extraction between steps.

Clients mix the Lysis Buffer with their cells and return the cell lysates to us for panel validation.

Once the targeted gene panel validation is complete, we will notify the client and ship a pilot batch of Targeted DRUG-seq library prep kits. Upon receiving the client's approval, we will commence production of the custom kit batch.


How does it work

  • Client communicates the genes of interest panel

    Gene panel submission form for Targeted BRB-seq or Targeted DRUG-seq
  • Alithea ships the Cell Lysis Buffer

  • Client transfers the lysates to the provided well plate and ships the samples to Alithea for panel validation

    Sample submission guidelines for MERCURIUSTM  Targeted DRUG-seq kits
  • 4 to 8 weeks

    Alithea develops and validates the custom detection panel on customer's samples

  • Client checkpoint - Alithea ships a pilot batch

  • Upon client's approval, Alithea begins the dedicated batch production of custom kits

  • Product specifications


    For (application)

    Targeted RNA sequencing

    For use with (equipment)

    Illumina®, AVIT™I and MGI instruments

    Species compatibility

    All eukaryotic species

    Shipping conditions

    Dry ice

    Storage conditions



  • Validated cell lines

      Cell line Specie Tissue Culture type
      A375 h.sapiens Skin, malignant melanoma adherent
      GM12878 h.sapiens PBMC, lymphoblastoid suspension
      H295R h.sapiens Adrenal gland, carcinoma adherent
      HAP1 h.sapiens KBM-7 derived, chronic
    myelogenous leukemia
      hASC h.sapiens Patient-derived adipose stromal cells adherent
      hASC-Adipocytes h.sapiens Differentiated hASC adherent
      HEK293 h.sapiens Kidney embryonic  adherent
      HeLa h.sapiens Cervix, adenocarcinoma adherent
      HepG2 h.sapiens Liver, carcinoma adherent
      Huh7 h.sapiens Liver, carcinoma adherent
      iNeurons h.sapiens Differentiated iPSC adherent
      MCF-7 h.sapiens Breast, adenocarcinoma adherent
      PANC-1 h.sapiens Pancreas, carcinoma adherent
      U2OS h.sapiens Bone, osteosarcoma adherent


  • Each Targeted DRUG-seq contains reagents (including four pairs of Unique Dual Indexing adapters) sufficient to complete the library preparation process for four different DRUG-seq pools.

    To note, the total number of RNA samples that can be processed with one kit does not exceed the kit specifications; for instance, a 96-sample kit can be used to prepare up to 96 samples distributed across up to four different libraries.

  • The recommended range of input material is in the range of 5’000-50’000 cells..

  • Targeted DRUG-seq is a 3’-end RNA sequencing method that requires significantly less sequencing than standard BRB-seq to achieve accurate gene quantification. Therefore, we recommend sequencing 100 reads per target for each sample, which enables reliable detection of the targeted genes.
  • The only difference between DRUG-seq and standard RNA-seq data analysis is the demultiplexing step, which assigns sequencing reads to their origin sample based on the DRUG-seq barcode sequence.

    For a thorough description of DRUG-seq data processing, please refer to the DRUG-seq kit user guide. 

Try our service

The MERCURIUS™ Targeted DRUG-seq service offers the most comprehensive, high-throughput and cost-efficient solution for targeted gene expression analysis projects starting from 2D cell cultures.

Discover our service

Speak with our RNA sequencing experts

Book a one-on-one call with one of our RNA experts to discover how we can assist your next project.